Williams ARW

No ORCID on file · 3 papers in corpus · active 2019-2023

Study types

  • article 1
  • other 1

Condition tags

  • adenomyosis 1
other 2023
Ulipristal acetate versus levonorgestrel-releasing intrauterine system for heavy menstrual bleeding (UCON): a randomised controlled phase III trial
EClinicalMedicine ·doi:10.1016/j.eclinm.2023.101995

BACKGROUND: Heavy menstrual bleeding affects one in four women and negatively impacts quality of life. Ulipristal acetate is prescribed to treat symptoms associated with uterine fibroids. We compared the effectiveness of ulipristal acetate …

article 2021
The endometrial response to modulation of ligand-progesterone receptor pathways is reversible
Fertility and sterility ·doi:10.1016/j.fertnstert.2021.02.008

ObjectiveTo study the impact of the progesterone receptor modulator (PRM), ulipristal acetate (UPA), on endometrial morphology and function.DesignCross-sectional.SettingUniversity Research Institute.Patient(s)Endometrial biopsies from 16 pa…

2019
A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids.
Human reproduction open ·doi:10.1093/hropen/hoz027

Study questionWhat is the safety and efficacy profile during long-term (12-24 months) uninterrupted treatment with the selective progesterone receptor modulator asoprisnil, 10 and 25 mg in women with heavy menstrual bleeding (HMB) associate…